2-bromo-1-(4-nitro-3-bromophenyl)ethanone | 56759-34-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-1-(4-nitro-3-bromophenyl)ethanone
• 英文别名: 2-Bromo-1-(3-bromo-4-nitrophenyl)ethanone
• CAS: 56759-34-3
• 化学式: C₈H₅Br₂NO₃
• 分子量: 322.941
• InChiKey: XWPGTESBZDAVHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(4-nitro-3-bromophenyl)ethanone 以88%的产率得到
  参考文献：
  名称：

  PASAVIBU S. J.; WILLIAMS L. R., AUSTRAL. J. CHEM. , 1975, 28, NO 5, 1023-1030

  摘要：

  DOI：
• 作为产物：
  描述：

  3'-溴-4'-硝基苯乙酮 在 溴 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以75%的产率得到2-bromo-1-(4-nitro-3-bromophenyl)ethanone
  参考文献：
  名称：

  [EN] PAN-GENOMIC INHIBITORS OF NS5A PROTEIN ENCODED BY HCV, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR INHIBITOR SYNTHESIS, AND THEIR SYNTHESIS AND APPLICATION METHODS.
  [FR] INHIBITEURS PAN-GÉNOMIQUES DE LA PROTÉINE NSSA CODÉE PAR LE VIRUS DE L'HÉPATITE C (VHC), COMPOSITIONS PHARMACEUTIQUES, INTERMÉDIAIRES POUR LA SYNTHÈSE DE CES INHIBITEURS, ET PROCÉDÉS DE SYNTHÈSE ET D'APPLICATION DE CEUX-CI

  摘要：

  由以下公式代表的化合物：或其药用可接受盐、水合物、结晶形式或立体异构体，其中：其中R11是可选择取代的C1-C6烷基、可选择取代的C3-C6环烷基或可选择取代的C1-C6烷氧基，箭头（<—）表示取代基的连接位置；R2是氢、卤素或C1-C4烷基；R3是可选择取代的芳基、可选择取代的芳氧基、可选择取代的芳基硫醚基、可选择取代的芳胺基或可选择取代的氮杂芳基；其中R41是可选择取代的C1-C6烷基、可选择取代的C3-C6环烷基或可选择取代的C1-C6烷氧基；X是丁-1,3-二炔基或1,4-苯基；箭头（<—）表示取代基的连接位置。

  公开号：

  WO2017039791A1

文献信息

• Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors
  作者：Andrey A. Ivashchenko、Yan A. Ivanenkov、Vladimir A. Aladinskiy、Ruben N. Karapetian、Angela G. Koryakova、Alexey A. Ryakhovskiy、Oleg D. Mitkin、Dmitry V. Kravchenko、Nikolai P. Savchuk、Bogdan A. Zagribelnyy、Alexander V. Ivashchenko

  DOI：10.1016/j.bmc.2020.115716

  日期：2020.10

  A series of novel small-molecule pan-genotypic hepatitis C virus (HCV) NS5A inhibitors with picomolar activity containing 2-[(2S)-pyrrolidin-2-yl]-5-[4-(4-2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}buta-1,3-diyn-1-yl) phenyl]-1H-imidazole core was designed based on molecular modeling study and SAR analysis. The constructed in silico model and docking study provide a deep insight into the binding mode of this type of NS5A inhibitors. Based on the predicted binding interface we have prioritized the most crucial diversity points responsible for improving antiviral activity. The synthesized molecules were tested in a cell-based assay, and compound 1.12 showed an EC50 value in the range of 2.9-34 pM against six genotypes of NS5A HCV, including gT3a, and demonstrated favorable pharmacokinetic profile in rats. This lead compound can be considered as an attractive candidate for further clinical evaluation.
• PAN-GENOMIC INHIBITORS OF NS5A PROTEIN ENCODED BY HCV, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR INHIBITOR SYNTHESIS, AND THEIR SYNTHESIS AND APPLICATION METHODS.
  申请人：Ivachtchenko, Alexandre Vasilievich

  公开号：EP3344617A1

  公开（公告）日：2018-07-11
• Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods
  申请人：Ivachtchenko Alexandre Vasilievich

  公开号：US20170066746A1

  公开（公告）日：2017-03-09

  Compound represented by formula 1: or a pharmaceutically acceptable salt, a hydrate, a crystalline form, or a stereoisomer thereof, wherein: R1 is hydrogen, tert-butoxycarbonyl, where R11 is an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 6 cycloalkyl, or an optionally substituted C 1 -C 6 alkyloxy, and arrows (←) indicate the position of substituents attachment; R2 is hydrogen, halogen, or C 1 -C 4 alkyl; R3 is an optionally substituted aryl, an optionally substituted aryloxy, an optionally substituted arylsulfanyl, an optionally substituted arylamino, or an optionally substituted nitrogen hetaryl; where R41 is an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 6 cycloalkyl, or an optionally substituted C 1 -C 6 alkyloxy; X is buta-1,3-diynylene or 1,4-phenylene; arrows (←) indicate the position of substituents attachment.
• US9790207B2
  申请人：——

  公开号：US9790207B2

  公开（公告）日：2017-10-17
• [EN] 5- AND 6- SUBSTITUTED BENZIMIDAZOLE THIOPHENE COMPOUNDS<br/>[FR] BENZIDIMIDAZOLE THIOPHÈNES SUBSTITUÉS EN 5 ET 6 POUR PLK
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2008070354A2

  公开（公告）日：2008-06-12

  [EN] The present invention provides 5- and 6-substituted benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
  [FR] La présente invention concerne des composés benzimidazole thiophène substitués en 5 et 6 et des compositions pharmaceutiques les contenant, des procédés pour les préparer et leur utilisation en tant qu'agents pharmaceutiques.